
@JohnSimpsonNews @wrunews @BBCSport @BBCWalesNews @BBCSportWales
✓Medical Oncologist. Hospital Univ. 12 de Octubre. Madrid. UCM. Head GU Unit. Executive Member @GUARDconsortitum

@JohnSimpsonNews @wrunews @BBCSport @BBCWalesNews @BBCSportWales

🧔 MOVEMBER | TIP DE INVESTIGACIÓN Al evaluar programas de detección del cáncer de próstata, no basta con mirar la prueba: también importan la identificación de la población, la información, el seguimiento y la calidad del programa. La IARC analizó estos requisitos en pilotos europeos: iarc.who.int/news-events/map… #Movember #CáncerDePróstata #Investigación @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🇦🇷 At #ESMOAI2026 in Berlin, we shared our survey of 181 people with cancer in Argentina. 46% had used generative AI for cancer-related questions. Only 40% of those users had discussed it with their doctor. Do we ask our patients about their AI use? @myESMO @aaoncoclinica

New @Annals_Oncology study exploring ctDNA-guided pembro in resected dMMR tumours. - 92% 2-year RFS in MRD- without treatment - Despite ⬆️clearance in treated MRD+, 38% relapsed. Sustained clearance may be more informative @OncoAlert @YJanjigianMD annalsofoncology.org/article…

🎯🎯 3º Scientific UroOncology Meeting (@UroOnco) to be held in Santiago de Chile !🇨🇱 Excellent program and spekears!! 💯 📅 20-21 November 👉 stay tuned via streaming !! @OncoAlert @aaoncoclinica @GuardConsortium @LAUrology_NL @DrFelixGuerrero @UroTeragLATAM @UroTarget @urotoday

JUST IN: the @FDA has declined to approve PD1/VEGF bispecific ivonescimab in advanced NSCLC with EGFRm, because of lack of OS benefit (via @Reuters) — Having seen approval in several cancers based on PFS, this is somewhat a puzzling rejection. reuters.com/legal/litigation…

🏆 Otro galardón para el #Hospital12deOctubre! 👏 Premio Best in Class al Mejor Servicio de Medicina Intensiva, por su excelencia en innovación, seguridad y humanización de atención al paciente crítico. 🔝 Compromiso y trabajo en equipo. 🔗 c.madrid/2rabq #somosdel12

🏆 El proyecto PRELUDE-PSMA de Medicina Nuclear y Radiofísica #H120, I Premio Nacional de Investigación en Teragnosis. 🔬 Objetivo: predecir la respuesta al tratamiento en tumor de próstata y avanzar hacia una oncología +personalizada. 🔗 c.madrid/h36aa #somosdel12

Not even a month after its results were presented the FDA has approved perioperative EV + durva for cis ineligible MIBC! A major advance for a population with historically limited treatment options 👏🏻 @OncoAlert Stay tuned for #UromigosLive @Uromigos ascopost.com/news/november-2…

Our paper IMPACT UTUC is now published in @NatRevUrol: an international multidisciplinary Delphi consensus on #UTUC doi.org/10.1038/s41585-026-0… @ricautor @RobertoContieri @LauraBukavinaMD @urodocash @PGrivasMDPhD @montypal @sonpavde @AndreaNecchi @jteoh_hk @carme_mir1

🚀 What if a simple blood draw could reveal not only tumor burden, but also PSMA expression, tumor lineage and emerging resistance? Super exciting #ESMO2026 data! 🧬 Comprehensive plasma epigenomic profiling from just 1 mL of plasma in mCRPC patients receiving ¹⁷⁷Lu-PSMA-617. 🔬 57 patients, 77 plasma samples 🎯 Plasma-derived PSMA estimates correlated with PSMA-PET and clinical outcomes 📉 At progression, predicted PSMA expression declined in 11/17 paired patients 🔄 Alternative targets, including TROP2 and STEAP1, were frequently retained or increased! Particularly fascinating: Plasma profiling identified distinct AR-driven, stem/EMT and proliferative tumor states associated with treatment outcomes. From liquid biopsy to functional tumor phenotyping—without another tissue biopsy! Could this technology eventually guide radioligand therapy selection and subsequent ADC sequencing? Important caveat: Exploratory congress data. Predicted target expression is not yet a clinically validated substitute for PET imaging or tissue assessment. #ProstateCancer #Theranostics #LiquidBiopsy @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

AI-based quantification of TROP2 subcellular distribution may predict Dato-DXd benefit in NSCLC @NatureMedicine Lower NMR correlated with greater ADC internalisation, potentially relevant given its stable linker @OncoAlert nature.com/articles/s41591-0…

🎯 🎯 @aaoncoclinica a new edition of @UroTarget 2026 is approaching!! 💯 Great panel, excellent speakers, amazing social events!! 💃💃 The most glamorous GU scientific meeting around the world!!@mflazzaro_gu @fedelosco @Martin_AngelMD @jpsade2 @OncoAlert @PGrivasMDPhD @DrChoueiri @ASCOPost @LauraBukavinaMD @AmandaNizamMD @apolo_andrea @Prof_Nick_James

🎥 CÁPSULA GUARD | Biomarcadores en tumores urológicos BRCA y FGFR, entre otros biomarcadores, forman parte de la conversación sobre cómo trasladar el conocimiento molecular a la práctica clínica. Descubre la cápsula del Dr. Nil Navarro 🎬 guardconsortium.org/investig… #Biomarcadores #OncologíaGU #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🎯 ADC targets are not necessarily stable! Exciting new UTUC study (n=141): Membranous NECTIN4 positivity: 🔹 Chemo-naive: 47% 🔹 Chemo-exposed: 9.3% TROP2 positivity: 🔹 Chemo-naive: 100% 🔹 Chemo-exposed: 97% Could prior chemotherapy reshape the ADC target landscape? Important implications for EV resistance and subsequent ADC sequencing! Target expression matters. Timing and tissue context may matter just as much. 🔬 @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

1/9 Our latest manuscript from the #CAPTURE platform in advanced #ProstateCancer is published in @EurUrolOncol. The prognostic impact of BRCA2 gene alterations has been well established, but is BRCA1 comparable to BRCA2? Are all non-BRCA HRR alterations equivalent? 🧵